Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
about
Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activityEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Potential for Improving Potency and Specificity of Reovirus Oncolysis with Next-Generation Reovirus VariantsCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesHigh efficiency of alphaviral gene transfer in combination with 5-fluorouracil in a mouse mammary tumor model.Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samplesOncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumorReovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal CancerSynergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.Reovirus in cancer therapy: an evidence-based reviewInactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis.Reovirus: a targeted therapeutic--progress and potential.Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.Optimization and preclinical design of genetically engineered viruses for human oncolytic therapy.Oncolytic reovirus type 3 (Dearing) as a novel therapy in head and neck cancer.HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus.Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Oncolytic virotherapy for urological cancers.Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus.BRAF- and MEK-Targeted Small Molecule Inhibitors Exert Enhanced Antimelanoma Effects in Combination With Oncolytic Reovirus Through ER Stress.Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan.Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.Concurrent chemotherapy inhibits herpes simplex virus-1 replication and oncolysis.Oncolytic vaccinia virus combined with radiotherapy induces apoptotic cell death in sarcoma cells by down-regulating the inhibitors of apoptosis.Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.Oncolytic vaccinia virus synergizes with irinotecan in colorectal cancer.Oncolytic reovirus induces intracellular redistribution of Ras to promote apoptosis and progeny virus release.Silencing of miR-193a-5p increases the chemosensitivity of prostate cancer cells to docetaxel.Oncolytic Virotherapy versus Cancer Stem Cells: A Review of Approaches and Mechanisms.Current understanding of reovirus oncolysis mechanisms.Magnetite-Gold nanohybrids as ideal all-in-one platforms for theranosticsDocetaxel increases the risk of severe infections in the treatment of non-small cell lung cancer: a meta-analysis
P2860
Q26750568-5628D797-2E08-49CB-8064-590A79D4F34AQ26775030-C73BD5C4-9958-485A-9C2D-920E19A0D430Q26775033-3694B3DF-9873-4C9D-97C6-6714D39D968CQ26863779-9A237E2C-CBE1-48D5-9B96-FA87D60A5B39Q33828697-3A11B404-5B09-4A79-AD86-6731FD027F1AQ34763999-0FFFB4D4-2BA7-4E39-AB92-036879BBB079Q36390114-229691F3-AC24-465B-B5D0-C6ABC6C6BAADQ36574519-5B74C400-5B96-483A-AA76-51E7F62930C5Q36757045-E9F07244-1AE1-4D63-84D6-B73408D27997Q36766052-20596AD6-BDDC-4EB3-84D5-B2F4AF378A8FQ37031909-CEF5445D-D7A2-4F28-A768-A3FABDC62B52Q37352017-63909262-AC87-41FF-A37C-920952C730CEQ37360608-2116B170-54C9-48EB-A05B-50F6D97D14E8Q37565521-A94FFEBB-FD48-4A13-8DE5-21FCE85ECE28Q38025696-700FAEB9-864C-4DDE-95A4-8B962DF52CB4Q38058884-D3445AA1-ADAE-497A-9BC8-980D23695867Q38458133-64EEEBBD-8F3B-4292-AC48-408B62E0BFF8Q38653084-92CEA6E8-8232-4F21-BC3E-52FB05504CCFQ38842126-DFE2335A-5D69-4F71-8277-EBB9E24D6984Q38844346-7DAAF500-06EB-4B3C-B6F1-6DF823DD212EQ38916660-A9CD67B5-7D20-4251-9A13-5D5BCBDB14EAQ38998279-9EEF7F6B-0911-4ADC-9DF3-744F7D430CA1Q39159172-19BD2A3A-DA88-41EA-8D26-FF3DB972CF21Q39205115-E407D5B3-E19C-459E-A1F5-6DC5F5DAEE20Q39247147-D4AD1EB9-7623-45FB-B751-6235D66BC015Q39247534-B8C59AD9-0D6D-4695-BF4D-4AD0B1DD9D65Q40907752-25E95596-5180-4E6C-B52F-1F96B50DC922Q40952636-2CFF20A2-0BED-4884-998D-842302B21A9FQ47096886-201ADA4B-5905-4156-B832-1BEF88B5AB24Q52718361-8E5D55D5-AC85-4D9D-A23B-6A262275BA74Q55427397-F396D453-9C63-4B7A-A5B4-D28684825AA0Q57181751-6F5E8BFC-0418-4B1D-9773-A72F7BFD6A3DQ58718145-02898AEE-139F-4304-A1D5-5FE7EF2DAE1D
P2860
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@ast
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en-gb
type
label
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@ast
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en-gb
prefLabel
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@ast
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en-gb
P2093
P2860
P356
P1433
P1476
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
@en
P2093
Angela Boxall
Guy R Simpson
Hardev S Pandha
Kate L Relph
Kevin J Harrington
Lucy Heinemann
Richard Morgan
Richard Vile
Robin Prestwich
Timothy Kottke
P2860
P2888
P356
10.1186/1471-2407-11-221
P407
P50
P577
2011-06-06T00:00:00Z
P5875
P6179
1007296371